T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989

Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review

Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320

The blockade of immune checkpoints in cancer immunotherapy

Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838

Safety, activity, and immune correlates of anti–PD-1 antibody in cancer

Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628

Oncology meets immunology: the cancer-immunity cycle.

Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929

PD-1 and Its Ligands in Tolerance and Immunity

Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378

Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation

Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231

Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion

Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025

The future of immune checkpoint therapy

Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878

Immune Checkpoints: Novel Therapeutic Targets to Attenuate Sepsis-Induced Immunosuppression

McBride, M. A., Patil, T. K., Bohannon, J. K., Hernandez, A., Sherwood, E. R., & Patil, N. K. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.624272 · Cited by 127

Molecular Pathways and Mechanisms of LAG3 in Cancer Therapy

Andrews, L. P., Cillo, A. R., Karapetyan, L., Kirkwood, J. M., Workman, C. J., & Vignali, D. A. A. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2390 · Cited by 122

Clinical implications of the interaction between PD-1/PD-L1 and PI3K/AKT/mTOR pathway in progression and treatment of non-small cell lung cancer

Quan, Z., Yang, Y., Zheng, H., Zhan, Y., Luo, J., Ning, Y., & Fan, S. (2022) · Journal of Cancer · doi:10.7150/jca.77619 · Cited by 129

Immune checkpoint inhibitors in advanced non–small cell lung cancer

Assi, H. I., Kamphorst, A. O., Moukalled, N. M., & Ramalingam, S. S. (2017) · Cancer · doi:10.1002/cncr.31105 · Cited by 123

Engineered triple inhibitory receptor resistance improves anti-tumor CAR-T cell performance via CD56

Zou, F., Lu, L., Liu, J., Xia, B., Zhang, W., Hu, Q., Liu, W., Zhang, Y., Lin, Y., Jing, S., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11893-4 · Cited by 120

Opportunities for Small Molecules in Cancer Immunotherapy

van der Zanden, S. Y., Luimstra, J. J., Neefjes, J., Borst, J., & Ovaa, H. (2020) · Trends in Immunology · doi:10.1016/j.it.2020.04.004 · Cited by 119

Double-edged roles of protein tyrosine phosphatase SHP2 in cancer and its inhibitors in clinical trials

Song, Y., Zhao, M., Zhang, H., & Yu, B. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107966 · Cited by 125

Immunotherapy for ovarian cancer: towards a tailored immunophenotype-based approach

Ghisoni, E., Morotti, M., Sarivalasis, A., Grimm, A. J., Kandalaft, L. E., Laniti, D. D., & Coukos, G. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00937-4 · Cited by 131

A comprehensive review of SHP2 and its role in cancer

Asmamaw, M. D., Shi, X.-J., Zhang, L.-R., & Liu, H.-M. (2022) · Cellular Oncology · doi:10.1007/s13402-022-00698-1 · Cited by 119

TIGIT Expression Is Associated with T-cell Suppression and Exhaustion and Predicts Clinical Outcome and Anti–PD-1 Response in Follicular Lymphoma

Yang, Z., Kim, H. J., Wu, H., Jalali, S., Tang, X., Krull, J. E., Ding, W., Novak, A. J., & Ansell, S. M. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0558 · Cited by 121

Immunotherapy combinations overcome resistance to bispecific T cell engager treatment in T cell–cold solid tumors

Belmontes, B., Sawant, D. V., Zhong, W., Tan, H. L. E., Kaul, A. M., Aeffner, F., O’Brien, S. A., Chun, M. G. H., Noubade, R., Eng, J. S., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abd1524 · Cited by 120

Senescent T cells within suppressive tumor microenvironments: emerging target for tumor immunotherapy

Liu, X., Hoft, D. F., & Peng, G. (2020) · Journal of Clinical Investigation · doi:10.1172/jci133679 · Cited by 116

Interruption of the intratumor CD8+ T cell:Treg crosstalk improves the efficacy of PD-1 immunotherapy

Geels, S. N., Moshensky, A., Sousa, R. S., Murat, C., Bustos, M. A., Walker, B. L., Singh, R., Harbour, S. N., Gutierrez, G., Hwang, M., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.05.013 · Cited by 124

Neoadjuvant PARPi or chemotherapy in ovarian cancer informs targeting effector Treg cells for homologous-recombination-deficient tumors

Luo, Y., Xia, Y., Liu, D., Li, X., Li, H., Liu, J., Zhou, D., Dong, Y. J., Li, X., Qian, Y., et al. (2024) · Cell · doi:10.1016/j.cell.2024.06.013 · Cited by 120

PD-1 Blockade and CD27 Stimulation Activate Distinct Transcriptional Programs That Synergize for CD8+ T-Cell–Driven Antitumor Immunity

Buchan, S. L., Fallatah, M., Thirdborough, S. M., Taraban, V. Y., Rogel, A., Thomas, L. J., Penfold, C. A., He, L.-Z., Curran, M. A., Keler, T., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3057 · Cited by 114

Type 1 conventional dendritic cells maintain and guide the differentiation of precursors of exhausted T cells in distinct cellular niches

Dähling, S., Mansilla, A. M., Knöpper, K., Grafen, A., Utzschneider, D. T., Ugur, M., Whitney, P. G., Bachem, A., Arampatzi, P., Imdahl, F., et al. (2022) · Immunity · doi:10.1016/j.immuni.2022.03.006 · Cited by 109

KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1

Bhatt, R. S., Berjis, A., Konge, J. C., Mahoney, K. M., Klee, A. N., Freeman, S. S., Chen, C.-H., Jegede, O. A., Catalano, P. J., Pignon, J., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0315 · Cited by 116

Exosomes: Their Role in Pathogenesis, Diagnosis and Treatment of Diseases

Aheget, H., Mazini, L., Martı́n, F., Belqat, B., Marchal, J. A., & Benabdellah, K. (2020) · Cancers · doi:10.3390/cancers13010084 · Cited by 113

Targeting Cancer Hallmarks with Epigallocatechin Gallate (EGCG): Mechanistic Basis and Therapeutic Targets

Talib, W. H., Awajan, D., Alqudah, A. M., Alsawwaf, R., Althunibat, R., AlRoos, M. A., Safadi, A. A., Asab, S. A., Hadi, R. W., & Kury, L. T. A. (2024) · Molecules · doi:10.3390/molecules29061373 · Cited by 111

The HVEM-BTLA Axis Restrains T Cell Help to Germinal Center B Cells and Functions as a Cell-Extrinsic Suppressor in Lymphomagenesis

Mintz, M. A., Felce, J. H., Chou, M. Y., Mayya, V., Xu, Y., Shui, J., An, J., Li, Z., Marson, A., Okada, T., et al. (2019) · Immunity · doi:10.1016/j.immuni.2019.05.022 · Cited by 117

Tumor microenvironment in chemoresistance, metastasis and immunotherapy of pancreatic cancer.

Wang, S., Li, Y., Cheng, X., Ding, C., Zhang, H., Chen, L., You, L., Dai, M., & Zhao, Y. (2020) · PubMed Central · Cited by 107

SHP-2 and PD-L1 Inhibition Combined with Radiotherapy Enhances Systemic Antitumor Effects in an Anti–PD-1–Resistant Model of Non–Small Cell Lung Cancer

Chen, D., Barsoumian, H. B., Yang, L., Younes, A. I., Verma, V., Hu, Y., Menon, H., Wasley, M., Masropour, F., Mosaffa, S., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0744 · Cited by 107

Bispecific Antibodies for Multiple Myeloma: A Review of Targets, Drugs, Clinical Trials, and Future Directions

Caraccio, C., Krishna, S., Phillips, D. J., & Schürch, C. M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00501 · Cited by 106

Topological analysis of hepatocellular carcinoma tumour microenvironment based on imaging mass cytometry reveals cellular neighbourhood regulated reversely by macrophages with different ontogeny

Sheng, J., Zhang, J., Wang, L., Tano, V., Tang, J., Wang, X., Wu, J., Song, J., Zhao, Y., Rong, J., et al. (2021) · Gut · doi:10.1136/gutjnl-2021-324339 · Cited by 107

Small-Molecule Inhibition of PD-1 Transcription Is an Effective Alternative to Antibody Blockade in Cancer Therapy

Taylor, A., Rothstein, D. M., & Rudd, C. E. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0491 · Cited by 107

Identification of a prognostic and therapeutic immune signature associated with hepatocellular carcinoma

Peng, Y., Liu, C., Li, M., Li, W., Zhang, M., Jiang, X. W., Chang, Y., Liu, L., Wang, F., & Zhao, Q. (2021) · Cancer Cell International · doi:10.1186/s12935-021-01792-4 · Cited by 109

The Cellular Immunotherapy Revolution: Arming the Immune System for Precision Therapy

Paucek, R. D., Baltimore, D., & Li, G. (2019) · Trends in Immunology · doi:10.1016/j.it.2019.02.002 · Cited by 104

Recent progress in tumor photodynamic immunotherapy

Shen, L., Zhou, T., Fan, Y., Chang, X. Y., Wang, Y., Sun, J., Xing, L., & Jiang, H. (2020) · Chinese Chemical Letters · doi:10.1016/j.cclet.2020.02.007 · Cited by 107

Immunotherapy Goes Local: The Central Role of Lymph Nodes in Driving Tumor Infiltration and Efficacy

van Pul, K. M., Fransen, M. F., van de Ven, R., & de Gruijl, T. D. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.643291 · Cited by 105

PD-L1–PD-1 interactions limit effector regulatory T cell populations at homeostasis and during infection

Perry, J. A., Shallberg, L. A., Clark, J. T., Gullicksrud, J. A., DeLong, J. H., Douglas, B. B., Hart, A. P., Lanzar, Z. R., O’Dea, K. M., Konradt, C., et al. (2022) · Nature Immunology · doi:10.1038/s41590-022-01170-w · Cited by 109

SHP2: A Pleiotropic Target at the Interface of Cancer and Its Microenvironment

Sodir, N. M., Pathria, G., Adamkewicz, J. I., Kelley, E. H., Sudhamsu, J., Merchant, M. A., Chiarle, R., & Maddalo, D. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0383 · Cited by 102

Coinhibitory Receptor Expression and Immune Checkpoint Blockade: Maintaining a Balance in CD8+ T Cell Responses to Chronic Viral Infections and Cancer

Okoye, I., Houghton, M., Tyrrell, D. L., Barakat, K., & Elahi, S. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01215 · Cited by 105

The Role of Immunotherapy in Pancreatic Cancer

Mukherji, R., Debnath, D., Hartley, M. L., & Noel, M. S. (2022) · Current Oncology · doi:10.3390/curroncol29100541 · Cited by 106

Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer

Ferrara, R., Imbimbo, M., Malouf, R. S., Paget‐Bailly, S., Calais, F., Marchal, C., & Westeel, V. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013257.pub3 · Cited by 101

The role of PD-1/PD-L1 axis and macrophage in the progression and treatment of cancer

Cai, J., Qi, Q., Qian, X., Han, J. G., Zhu, X., Zhang, Q., & Xia, R. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-019-02879-2 · Cited by 103

Blockades of effector T cell senescence and exhaustion synergistically enhance antitumor immunity and immunotherapy

Liu, X., Si, F., Bagley, D., Ma, F., Zhang, Y., Tao, Y., Shaw, E. C., & Peng, G. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005020 · Cited by 104

Deletion of SNX9 alleviates CD8 T cell exhaustion for effective cellular cancer immunotherapy

Trefny, M. P., Kirchhammer, N., der Maur, P. A., Natoli, M., Schmid, D., Germann, M., Fernandez-Rodriguez, L., Herzig, P., Lötscher, J., Akrami, M., et al. (2023) · Nature Communications · doi:10.1038/s41467-022-35583-w · Cited by 98

Cas9-edited immune checkpoint blockade PD-1 DNA polyaptamer hydrogel for cancer immunotherapy

Lee, J., Le, Q., Yang, G., & Oh, Y. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119359 · Cited by 99

Peptide-based and small synthetic molecule inhibitors on PD-1/PD-L1 pathway: A new choice for immunotherapy?

Chen, T., Li, Q., Liu, Z., Chen, Y., Feng, F., & Sun, H. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.10.044 · Cited by 100

Clinical Pharmacology and Interplay of Immune Checkpoint Agents: A Yin-Yang Balance

Géraud, A., Gougis, P., Vozy, A., Anquetil, C., Allenbach, Y., Romano, E., Funck‐Brentano, E., Moslehi, J. J., Johnson, D. B., & Salem, J. (2020) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-022820-093805 · Cited by 97

The CD58-CD2 axis is co-regulated with PD-L1 via CMTM6 and shapes anti-tumor immunity

Ho, P., Melms, J. C., Rogava, M., Frangieh, C. J., Poźniak, J., Shah, S. B., Walsh, Z. H., Kyrysyuk, O., Amin, A. D., Caprio, L., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.05.014 · Cited by 103

Exosomal PD‐L1: New Insights Into Tumor Immune Escape Mechanisms and Therapeutic Strategies

Zhou, K., Guo, S., Li, F., Sun, Q., & Liang, G. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.569219 · Cited by 99

Allosteric Inhibition of SHP2 Stimulates Antitumor Immunity by Transforming the Immunosuppressive Environment

Quintana, E., Schulze, C. J., Myers, D. R., Choy, T. J., Mordec, K., Wildes, D. P., Shifrin, N. T., Belwafa, A., Koltun, E. S., Gill, A. L., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-3038 · Cited by 94

Biomimetic Anti‐PD‐1 Peptide‐Loaded 2D FePSe 3 Nanosheets for Efficient Photothermal and Enhanced Immune Therapy with Multimodal MR/PA/Thermal Imaging

Fang, X., Wu, X., Li, Z., Jiang, L., Lo, W., Chen, G., Gu, Y., & Wong, W. (2020) · Advanced Science · doi:10.1002/advs.202003041 · Cited by 96

Targeting human Acyl-CoA:cholesterol acyltransferase as a dual viral and T cell metabolic checkpoint

Schmidt, N. M., Wing, P. A. C., Diniz, M. O., Pallett, L. J., Swadling, L., Harris, J. M., Burton, A. R., Jeffery-Smith, A., Zakeri, N., Amin, O. E., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22967-7 · Cited by 96

PD-1 agonism by anti-CD80 inhibits T cell activation and alleviates autoimmunity

Sugiura, D., Okazaki, I., Maeda, T. K., Maruhashi, T., Shimizu, K., Arakaki, R., Takemoto, T., Ishimaru, N., & Okazaki, T. (2022) · Nature Immunology · doi:10.1038/s41590-021-01125-7 · Cited by 102

Tumor-targeted CD28 bispecific antibodies enhance the antitumor efficacy of PD-1 immunotherapy

Waite, J. C., Wang, B., Haber, L., Hermann, A., Ullman, E., Ye, X., Dudgeon, D., Slim, R. M., Ajithdoss, D. K., Godin, S., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aba2325 · Cited by 100

CD8 + T cell exhaustion in anti‐tumour immunity: The new insights for cancer immunotherapy

Huang, Y., Jia, A., Wang, Y., & Liu, G. (2022) · Immunology · doi:10.1111/imm.13588 · Cited by 96

Regulation of CD8+ T memory and exhaustion by the mTOR signals

Chen, Y., Xu, Z., Sun, H., Ouyang, X., Han, Y., Yu, H., Wu, N., Xie, Y., & Su, B. (2023) · Cellular and Molecular Immunology · doi:10.1038/s41423-023-01064-3 · Cited by 101

SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK Inhibitors

Lu, H., Liu, C., Velazquez, R., Wang, H., Dunkl, L. M., Kazic-Legueux, M., Haberkorn, A., Billy, E., Manchado, E., Brachmann, S. M., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0852 · Cited by 90

Mitochondrial Morphological and Functional Reprogramming Following CD137 (4-1BB) Costimulation

Teijeira, Á., Labiano, S., Garasa, S., Etxeberría, I., Santamaría, E., Rouzaut, A., Enamorado, M., Azpilikueta, A., Inogés, S., Bolaños, E., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0767 · Cited by 99

New insights into the pharmacological, immunological, and CAR-T-cell approaches in the treatment of hepatocellular carcinoma

Bo, M. D., Mattia, E. D., Baboçi, L., Mezzalira, S., Cecchin, E., Assaraf, Y. G., & Toffoli, G. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100702 · Cited by 94

Affinity purification mass spectrometry analysis of PD-1 uncovers SAP as a new checkpoint inhibitor

Peled, M., Tocheva, A. S., Sandigursky, S., Nayak, S., Philips, E. A., Nichols, K. E., Strazza, M., Azoulay-Alfaguter, I., Askenazi, M., Neel, B. G., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1710437115 · Cited by 87

Immune Suppression by PD-L2 against Spontaneous and Treatment-Related Antitumor Immunity

Tanegashima, T., Togashi, Y., Azuma, K., Kawahara, A., Ideguchi, K., Sugiyama, D., Kinoshita, F., Akiba, J., Kashiwagi, E., Takeuchi, A., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3991 · Cited by 93

Signaling pathways in brain tumors and therapeutic interventions

Li, S., Wang, C., Chen, J., Lan, Y., Zhang, W., Kang, Z., Zheng, Y., Zhang, R., Yu, J., & Li, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01260-z · Cited by 105

SHP-2 and PD-1-SHP-2 signaling regulate myeloid cell differentiation and antitumor responses

Christofides, A., Katopodi, X.-L., Cao, C., Karagkouni, D., Aliazis, K., Yenyuwadee, S., Aksoylar, H., Pal, R., Mahmoud, M. A. A., Strauss, L., et al. (2022) · Nature Immunology · doi:10.1038/s41590-022-01385-x · Cited by 96

In vitro reconstitution of T cell receptor-mediated segregation of the CD45 phosphatase

Carbone, C. B., Kern, N., Fernandes, R. A., Hui, E., Su, X., García, K. C., & Vale, R. D. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1710358114 · Cited by 91

Cytotoxic CD8+ Lymphocytes in the Tumor Microenvironment

Iwahori, K. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-35723-8_4 · Cited by 102

Functional categories of immune inhibitory receptors

Rumpret, M., Drylewicz, J., Ackermans, L. J. E., Borghans, J. A. M., Medzhitov, R. M., & Meyaard, L. (2020) · Nature reviews. Immunology · doi:10.1038/s41577-020-0352-z · Cited by 94

Spatial Regulation of T‑Cell Signaling by Programmed Death-Ligand 1 on Wireframe DNA Origami Flat Sheets

Fang, T., Alvelid, J., Spratt, J., Ambrosetti, E., Testa, I., & Teixeira, A. I. (2021) · ACS Nano · doi:10.1021/acsnano.0c10632 · Cited by 91

The role of the tumour microenvironment in immunotherapy

Gasser, S., Lim, L. H. K., & Cheung, F. S. G. (2017) · Endocrine Related Cancer · doi:10.1530/erc-17-0146 · Cited by 90

The structural features that distinguish PD-L2 from PD-L1 emerged in placental mammals

Philips, E. A., García‐España, A., Tocheva, A. S., Ahearn, I. M., Adam, K. R., Pan, R., Mor, A., & Kong, X. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ac119.011747 · Cited by 98

Resistance to PD-L1/PD-1 Blockade Immunotherapy. A Tumor-Intrinsic or Tumor-Extrinsic Phenomenon?

Chocarro, L., Zuazo, M., Arasanz, H., Bocanegra, A., Hernandez, C., Fernández, G., García-Granda, M. J., Blanco, E., Vera, R., Kochan, G. T., et al. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00441 · Cited by 94

Tumor-Secreted Extracellular Vesicles Regulate T-Cell Costimulation and Can Be Manipulated To Induce Tumor-Specific T-Cell Responses

Zhao, X., Yuan, C., Wangmo, D., & Subramanian, S. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.04.036 · Cited by 93

IFNAR1 Controls Autocrine Type I IFN Regulation of PD-L1 Expression in Myeloid-Derived Suppressor Cells

Xiao, W. L., Klement, J. D., Lu, C., Ibrahim, M. L., & Liu, K. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1800129 · Cited by 90

Costimulatory Molecules and Immune Checkpoints Are Differentially Expressed on Different Subsets of Dendritic Cells

Carenza, C., Calcaterra, F., Oriolo, F., Vito, C. D., Ubezio, M., Porta, M. G. D., Mavilio, D., & Bella, S. D. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01325 · Cited by 91

Time to dissect the autoimmune etiology of cancer antibody immunotherapy

Dougan, M. L., & Pietropaolo, M. (2020) · Journal of Clinical Investigation · doi:10.1172/jci131194 · Cited by 92

Type I IFN activating type I dendritic cells for antitumor immunity

Liang, Y., Hannan, R., & Fu, Y.-X. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2564 · Cited by 91

A Portrait of CXCR5+ Follicular Cytotoxic CD8+ T cells

Yu, D., & Ye, L. (2018) · Trends in Immunology · doi:10.1016/j.it.2018.10.002 · Cited by 92

Optimization of Fused Bicyclic Allosteric SHP2 Inhibitors

Bagdanoff, J. T., Chen, Z., Acker, M., Chen, Y., Chan, H., Dore, M., Firestone, B., Fodor, M., García‐Fortanet, J., Hentemann, M., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01725 · Cited by 92

PD-1 blockade-unresponsive human tumor-infiltrating CD8+ T cells are marked by loss of CD28 expression and rescued by IL-15

Kim, K. H., Kim, H. K., Kim, H., Kim, C. G., Lee, H., Han, J. W., Choi, S. J., Jeong, S., Jeon, M., Kim, H., et al. (2020) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-0427-6 · Cited by 90

PD-1-mediated inhibition of T cell activation: Mechanisms and strategies for cancer combination immunotherapy

Liu, R., Li, H., & Li, S. (2024) · Cell Insight · doi:10.1016/j.cellin.2024.100146 · Cited by 96

PD-1 and TIGIT downregulation distinctly affect the effector and early memory phenotypes of CD19-targeting CAR T cells

Lee, Y.-H., Lee, H. J., Kim, H. C., Lee, Y., Nam, S. K., Hupperetz, C., Ma, J. S. Y., Wang, X., Singer, O., Kim, W. S., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.10.004 · Cited by 89

Overriding Adaptive Resistance to Sorafenib Through Combination Therapy With Src Homology 2 Domain–Containing Phosphatase 2 Blockade in Hepatocellular Carcinoma

Leung, C. O. N., Tong, M., Chung, K. P. S., Zhou, L., Che, N., Tang, K. H., Ding, J., Lau, E. Y.-T., Ng, I. O., Ma, S., et al. (2019) · Hepatology · doi:10.1002/hep.30989 · Cited by 88

PD-1 blockade increases the self-renewal of stem-like CD8 T cells to compensate for their accelerated differentiation into effectors

Gill, A. L., Wang, P. H., Lee, J., Hudson, W. H., Ando, S., Araki, K., Hu, Y., Wieland, A., Im, S. J., Gavora, A. A., et al. (2023) · Science Immunology · doi:10.1126/sciimmunol.adg0539 · Cited by 95

Revolutionizing Cancer Treatment: Recent Advances in Immunotherapy

Ghemrawi, R., Abuamer, L., Kremesh, S., Hussien, G., Ahmed, R., Mousa, W. K., Khoder, G., & Khair, M. (2024) · Biomedicines · doi:10.3390/biomedicines12092158 · Cited by 97

Rejuvenation of tumour-specific T cells through bispecific antibodies targeting PD-L1 on dendritic cells

Liu, L., Chen, J., Bae, J., Li, H., Sun, Z., Moore, C., Hsu, E. J., Han, C., Qiao, J., & Fu, Y. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00800-2 · Cited by 87

Immune-related adverse effects of checkpoint immunotherapy and implications for the treatment of patients with cancer and autoimmune diseases

Ibis, B., Aliazis, K., Cao, C., Yenyuwadee, S., & Boussiotis, V. A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1197364 · Cited by 92

Characteristics and anatomic location of PD-1 + TCF1 + stem-like CD8 T cells in chronic viral infection and cancer

Im, S. J., Obeng, R. C., Nasti, T. H., McManus, D. T., Kamphorst, A. O., Gunisetty, S., Prokhnevska, N., Carlisle, J. W., Yu, K., Sica, G., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2221985120 · Cited by 88

Mechanisms of resistance to tyrosine kinase inhibitor‐targeted therapy and overcoming strategies

Ou, X., Gao, G., Habaz, I. A., & Wang, Y. (2024) · MedComm · doi:10.1002/mco2.694 · Cited by 104

CAR-T cell therapy: developments, challenges and expanded applications from cancer to autoimmunity

Kong, Y., Li, J., Zhao, X., Wu, Y., & Chen, L. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1519671 · Cited by 96

Regulators of CD8+ T cell exhaustion

Sun, Q., & Dong, C. (2025) · Nature reviews. Immunology · doi:10.1038/s41577-025-01221-x · Cited by 91

Determinants of Ligand-Functionalized DNA Nanostructure–Cell Interactions

Cremers, G. A. O., Rosier, B. J. H. M., Meijs, A., Tito, N. B., van Duijnhoven, S. M. J., van Eenennaam, H., Albertazzi, L., & de Greef, T. F. A. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.1c02298 · Cited by 79

Genetic and Epigenetic Biomarkers of Immune Checkpoint Blockade Response

Xiao, Q., Nobre, A., Piñeiro, P., Berciano‐Guerrero, M., Alba, E., Cobo, M., Lauschke, V. M., & Barragán, I. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9010286 · Cited by 82

KLHL22 maintains PD-1 homeostasis and prevents excessive T cell suppression

Zhou, X. A., Zhou, J., Zhao, L., Yu, G., Zhan, J., Shi, C., Yuan, R., Wang, Y., Chen, C., Zhang, W., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2004570117 · Cited by 82

First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response

Yap, T. A., Gainor, J. F., Callahan, M. K., Falchook, G. S., Pachynski, R. K., LoRusso, P. M., Kummar, S., Gibney, G. T., Burris, H. A., Tykodi, S. S., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-4256 · Cited by 84

PD‐1 suppresses TCR‐CD8 cooperativity during T‐cell antigen recognition

Li, K., Yuan, Z., Lyu, J., Ahn, E., Davis, S. J., Ahmed, R., & Zhu, C. (2021) · Nature Communications · doi:10.1038/s41467-021-22965-9 · Cited by 81

CD28 Costimulatory Domain–Targeted Mutations Enhance Chimeric Antigen Receptor T-cell Function

Boucher, J. C., Li, G., Kotani, H., Cabral, M. L., Morrissey, D., Lee, S. B., Spitler, K., Beatty, N. J., Cervantes, E. V., Shrestha, B., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0253 · Cited by 82

Cell-targeted PD-1 agonists that mimic PD-L1 are potent T cell inhibitors

Curnock, A. P., Bossi, G., Kumaran, J., Bawden, L. J., Figueiredo, R., Tawar, R., Wiseman, K., Henderson, E., Hoong, S.-J., Gonzalez, V., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.152468 · Cited by 80

Blockade of novel immune checkpoints and new therapeutic combinations to boost antitumor immunity

Archilla‐Ortega, A., Domuro, C., Martín-Liberal, J., & Muñoz, P. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02264-x · Cited by 79

CAR affinity modulates the sensitivity of CAR-T cells to PD-1/PD-L1-mediated inhibition

Andreu-Saumell, I., Rodríguez-García, A., Mühlgrabner, V., Giménez-Alejandre, M., Marzal, B., Castellsagué, J., Brasó‐Maristany, F., Calderón, H., Angelats, L., Colell, S., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47799-z · Cited by 87

mRNA vaccine with unmodified uridine induces robust type I interferon-dependent anti-tumor immunity in a melanoma model

Sittplangkoon, C., Alameh, M.-G., Weissman, D., Lin, P. J. C., Tam, Y. K., Prompetchara, E., & Palaga, T. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.983000 · Cited by 79

LPA5 Is an Inhibitory Receptor That Suppresses CD8 T-Cell Cytotoxic Function via Disruption of Early TCR Signaling

Mathew, D., Kremer, K. N., Strauch, P., Tigyi, G., Pelanda, R., & Torres, R. M. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01159 · Cited by 82

Recharacterizing Tumor-Infiltrating Lymphocytes by Single-Cell RNA Sequencing

Zhang, L., & Zhang, Z. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0658 · Cited by 77

Wnts and the hallmarks of cancer

Zhong, Z., Yu, J., Virshup, D. M., & Madan, B. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09887-6 · Cited by 81

Human CD8+HLA-DR+ Regulatory T Cells, Similarly to Classical CD4+Foxp3+ Cells, Suppress Immune Responses via PD-1/PD-L1 Axis

Machicote, A., Belén, S., Baz, P., Billordo, L. A., & Fainboim, L. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02788 · Cited by 81

T-Cell Mechanobiology: Force Sensation, Potentiation, and Translation

Harrison, D. L., Fang, Y. H., & Huang, J. (2019) · Frontiers in Physics · doi:10.3389/fphy.2019.00045 · Cited by 83

The Roles of Exosomal Proteins: Classification, Function, and Applications

Li, X., Yang, L.-X., Wang, C., Li, H., Shi, D., & Wang, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043061 · Cited by 82

Mass Cytometry Analysis Reveals that Specific Intratumoral CD4+ T Cell Subsets Correlate with Patient Survival in Follicular Lymphoma

Yang, Z., Kim, H. J., Villasboas, J. C., Price-Troska, T. L., Jalali, S., Wu, H., Luchtel, R. A., Polley, M. C., Novak, A. J., & Ansell, S. M. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.01.085 · Cited by 77

Co-Stimulatory Receptors in Cancers and Their Implications for Cancer Immunotherapy

Jeong, S., & Park, S. (2020) · Immune Network · doi:10.4110/in.2020.20.e3 · Cited by 78

PD-1 targets CD28

Dempsey, L. A. (2017) · Nature Immunology · doi:10.1038/ni.3739 · Cited by 3

PD-1 Primarily Targets TCR Signal in the Inhibition of Functional T Cell Activation

Mizuno, R., Sugiura, D., Shimizu, K., Maruhashi, T., Watada, M., Okazaki, I., & Okazaki, T. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00630 · Cited by 186

Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2

Yokosuka, T., Takamatsu, M., Kobayashi-Imanishi, W., Hashimoto-Tane, A., Azuma, M., & Saito, T. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20112741 · Cited by 1,161

PD-1 Blockade–Mediated Rescue of Exhausted T Cells Requires CD28

(2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-rw2017-055 · Cited by 1

PD1 functions by inhibiting CD28‐mediated co‐stimulation

O’Donnell, J. S., Smyth, M. J., & Teng, M. W. L. (2017) · Clinical & Translational Immunology · doi:10.1038/cti.2017.15 · Cited by 10